BLISS-LN (2020) — Trial Summary
BLISS-LN (2020): The BLISS-LN trial evaluated the efficacy and safety of belimumab, a B-lymphocyte stimulator inhibitor, added to standard therapy in patients with active lupus nephritis.
References
- Furie R, Rovin BH, Houssiau F, et al. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. N Engl J Med. 2020;383(12):1117-1128.